BRPI0509583A - composições farmacêuticas de pirimidina-2,4,6-trionas - Google Patents

composições farmacêuticas de pirimidina-2,4,6-trionas

Info

Publication number
BRPI0509583A
BRPI0509583A BRPI0509583-2A BRPI0509583A BRPI0509583A BR PI0509583 A BRPI0509583 A BR PI0509583A BR PI0509583 A BRPI0509583 A BR PI0509583A BR PI0509583 A BRPI0509583 A BR PI0509583A
Authority
BR
Brazil
Prior art keywords
triones
pyrimidine
pharmaceutical compositions
trioxopyrimidine
derivative
Prior art date
Application number
BRPI0509583-2A
Other languages
English (en)
Inventor
Pierre Bartsch
Didier Cataldo
Richard Endele
Brigitte Evrard
Jean-Michel Foidart
Hans-Willi Krell
Gerd Zimmermann
Original Assignee
Hoffmann La Roche
Univ Li Ge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Univ Li Ge filed Critical Hoffmann La Roche
Publication of BRPI0509583A publication Critical patent/BRPI0509583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Nanotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

COMPOSIçõES FARMACêUTICAS DE PIRIMIDINA-2,4,6-TRIONAS. A presente invenção refere-se a um complexo de trioxopirimidina-ciclodextrina formado por um derivado de trioxopirimidina ou seu sal e um derivado de ciclodextrina solúvel em água que tem melhor solubilidade.
BRPI0509583-2A 2004-04-01 2005-03-31 composições farmacêuticas de pirimidina-2,4,6-trionas BRPI0509583A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007921 2004-04-01
PCT/EP2005/003348 WO2005097058A2 (en) 2004-04-01 2005-03-31 Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones

Publications (1)

Publication Number Publication Date
BRPI0509583A true BRPI0509583A (pt) 2007-10-09

Family

ID=34924547

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509583-2A BRPI0509583A (pt) 2004-04-01 2005-03-31 composições farmacêuticas de pirimidina-2,4,6-trionas

Country Status (11)

Country Link
US (2) US20070191404A1 (pt)
EP (1) EP1735007A2 (pt)
JP (1) JP4787240B2 (pt)
KR (1) KR100771411B1 (pt)
CN (1) CN1950110B (pt)
AU (1) AU2005230380B2 (pt)
BR (1) BRPI0509583A (pt)
CA (1) CA2561660C (pt)
MX (1) MXPA06011031A (pt)
RU (1) RU2411043C2 (pt)
WO (1) WO2005097058A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191404A1 (en) 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
US10653899B2 (en) 2009-12-31 2020-05-19 Sol-Gel Technologies Ltd. Core stabilized microcapsules, method of their preparation and uses thereof
KR20220156931A (ko) * 2020-03-23 2022-11-28 잡 리써치 앤드 디벨롭먼트, 엘엘씨 경구 테르펜 사이클로덱스트린 봉입물 복합 비히클

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1018340B (de) * 1954-01-13 1957-10-24 Takeo Takagi Vorrichtung zum Reissen und Strecken eines Buendels aus endlosen Kunstfaeden nach dem Doppelstrecksystem
DE19548624A1 (de) * 1995-12-23 1997-06-26 Boehringer Mannheim Gmbh Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19726427A1 (de) * 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
ATE249218T1 (de) * 1999-01-06 2003-09-15 Tecnimede Sociedade Tecnico Medicinal Sa Cyclodextrin einschlusskomplexe mit aminosäuresalzen von benzimidazolderivaten, deren herstellung, sowie diese enthaltende pharmazeutische zusammensetzungen
AR033651A1 (es) * 1999-10-01 2004-01-07 Hoffmann La Roche Derivados de pirimidina-2,4,6-triona, composiciones farmaceuticas que contienen dichos compuestos y el empleo de los mismos para la manufactura de un medicamento
WO2002089824A1 (en) * 2001-05-03 2002-11-14 F. Hoffmann-La Roche Ag Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
US20070191404A1 (en) 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones

Also Published As

Publication number Publication date
US20100261672A1 (en) 2010-10-14
JP4787240B2 (ja) 2011-10-05
JP2007530628A (ja) 2007-11-01
AU2005230380A1 (en) 2005-10-20
US8044035B2 (en) 2011-10-25
CA2561660C (en) 2012-10-30
WO2005097058A3 (en) 2006-08-17
KR100771411B1 (ko) 2007-10-30
CN1950110A (zh) 2007-04-18
RU2006138431A (ru) 2008-06-10
US20070191404A1 (en) 2007-08-16
RU2411043C2 (ru) 2011-02-10
MXPA06011031A (es) 2007-03-21
KR20070027528A (ko) 2007-03-09
CN1950110B (zh) 2012-11-21
EP1735007A2 (en) 2006-12-27
AU2005230380B2 (en) 2010-09-23
CA2561660A1 (en) 2005-10-20
WO2005097058A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
BRPI0519316B8 (pt) composição aquosa herbicida, e, processo para a preparação de uma composição
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0910057A2 (pt) composições cosméticas decorativas
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
BRPI0514766A (pt) composições farmacêuticas
BR0109931A (pt) Composições farmacêuticas
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
BRPI0606280A2 (pt) composições de bisfosfonato nanoparticulado
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
BRPI0608291A2 (pt) agente imunossupressor e agente antitumoral que compreendem composto heterocìclico como ingrediente ativo
BRPI0814957B8 (pt) composto, agente farmacêutico, e, uso do composto
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
CY1113824T1 (el) Ενδορινικες συνθεσεις
GT200600063A (es) Tetraciclinas 9-sustituidas
CR9993A (es) Formulación de suspensión de fexofenadina
ATE406161T1 (de) Kombination aus tenofovir, ritonavir und tmc114
CR9857A (es) Composiciones de suplemento de hierro con tolerancia mejorada
ATE530188T1 (de) Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
BRPI0519764A2 (pt) composiÇÕes farmacÊuticas derivadas de Ácido xanturÊnico e mÉtodos relacionados a estas
BRPI0608287A2 (pt) agente endoparasiticida
MX2007010930A (es) Formulacion de aviptadil.
BRPI0509583A (pt) composições farmacêuticas de pirimidina-2,4,6-trionas
GB2453402A (en) Bis-pyyrolo[2.1.-c] benzodiazepine-anthraquinone conjugates as antitumour agents and a process for the preparation thereof
NO20075218L (no) Dermatological compositions and salts for the treatment of dermatological diseases

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: UNIVERSITE DE LIEGE (BE)

Free format text: TRANSFERIDO DE: F. HOFFMANN-LA ROCHE AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 31/198 (2006.01), A61K 3